Compare HTO & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTO | TYRA |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | 837 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2021 |
| Metric | HTO | TYRA |
|---|---|---|
| Price | $58.19 | $32.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $62.00 | $47.50 |
| AVG Volume (30 Days) | 430.2K | ★ 731.1K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $17.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.75 | $8.75 |
| 52 Week High | $61.87 | $40.65 |
| Indicator | HTO | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 40.05 |
| Support Level | $55.37 | $30.10 |
| Resistance Level | $58.77 | $33.99 |
| Average True Range (ATR) | 1.33 | 1.98 |
| MACD | 0.08 | -0.26 |
| Stochastic Oscillator | 89.31 | 4.68 |
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.